INTRODUCTION
This discussion-based activity will inform and guide on the latest practice-changing evidence for adjuvant and neoadjuvant approaches in the treatment of early-stage non-small cell lung cancer (NSCLC).
Launch Date: September 12, 2022
Expiration Date: August 31, 2023
TARGET AUDIENCE
This program is intended for clinicians who treat/manage patients with non-small cell lung cancer. This includes community and institution based medical oncologists, surgical oncologists, pulmonologists, and other oncology healthcare providers (nurse practitioners. physician assistants and nurses).
LEARNING OBJECTIVES
Upon completion of this enduring material, participants should be better able to:
METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
- There are no fees for participating in and receiving credit for this enduring material.
- Review the learning objectives and activity information.
- Review all modules associated with this activity.
- Successfully complete the post-test ( accuracy or better).
- Complete the online evaluation.
- The estimated time to complete this enduring material is hour(s).
- Upon successful completion, your AMA or ANCC certificate will be emailed to you.
ACCREDITATION STATEMENTS
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Practice Point Communications, Inc. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.
DISCLOSURE INFORMATION
In compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, it is the policy for all accreditors of this accredited continuing education activity as named above to ensure accuracy, balance, objectivity, independence, and scientific rigor in all their educational activities, and to commit to protecting learners from promotion, marketing, and commercial bias. All faculty, planners and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. This enduring material may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of the accredited providers and Practice Point Communications.
DISCLOSURES
The accredited providers have mitigated and are disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:
PLANNING COMMITTEE DISCLOSURE INFORMATION
The below planning committee members have nothing to disclose:
UNMC: Omar Abughanimeh, MBBS; Valeta Creason-Wahl; Heidi Keeler, PhD, RN; Renee Paulin, MSN, RN, CWOCN; Brenda Ram, CMP, CHCP
PPC: Nirupama Mulherkar, Martin Stevens, Jill Valone
FACULTY DISCLOSURES
Julie R. Brahmer, MD, MSc
Grant Research Funding: AstraZeneca, Bristol-Myers Squibb
Advisory Board: Janssen
Jamie Chaft, MD
Consultant: AstraZeneca, Bristol-Myers Squibb, Flame Biosciences, Genentech, Guardant Health, Janssen, Merck, Novartis, Regeneron
Stephen Liu, MD
Consultant: Amgen, AstraZeneca, Bayer, Beigene, Blueprint, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech, Gilead Sciences, Guardant Health, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics
Grant Research Funding: Bayer, Blueprint, Bristol-Myers Squibb, Elevation Oncology, Genentech, Gilead Sciences, Lilly, Merck, Nuvalent, Pfizer, Rain, RAPT, Turning Point Therapeutics
PRIVACY POLICY
The University of Nebraska Medical Center and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The University of Nebraska Medical Center and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME and ANCC.
The University of Nebraska Medical Center and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
COPYRIGHT INFORMATION
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.
HARDWARE/SOFTWARE REQUIREMENTS
Computer:
- Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
- Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
- Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.
Software/Browser:
- Windows 7 or above running Internet Explorer 10 or above.
- MAC OSX 10.5 (Leopard) or above running Safari 6 or above, or any version of Chrome, Firefox or Opera published in the last two years.
- A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.
Mobile Device:
- Any Apple iPad or iPad Mini running iOS 7.1 or above.
- Android tablets such as the Kindle Fire or Samsung Galaxy S.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
Supported by an independent educational grant from Merck Sharp & Dohme, LLC.